Last reviewed · How we verify

NCT04199494: BIOSTEPS

Antibiotic Stewardship Program in Pancreatic Surgery: a Multicenter Time Series Analysis (BIOSTEPS).

Status unknown Last updated 19 February 2020
What this trial tests

trial testing Antibiotic Stewardship Program in Surgical Site Infection in 1,200 participants. Status unknown.

Timeline
16 December 2019
Primary endpoint
1 September 2022
16 December 2022

Quick facts

Lead sponsorAzienda Ospedaliera Universitaria Integrata Verona
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment1,200
Start date16 December 2019
Primary completion1 September 2022
Estimated completion16 December 2022
Sites2 locations across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Azienda Ospedaliera Universitaria Integrata Verona — full company profile →

Who can join

18 and older, any sex, with Surgical Site Infection or Antibiotic Resistant Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Rationale: Surgical site infection (SSI) is one of the most frequently reported postoperative complication, occurring in up to one-third of patients. Its development causes a substantial increase in the clinical and economic burden of pancreatic surgery. Nowadays, the primary goal of a surgical department is the reduction of the SSI rate, based on a cautious approach to the prescription of the antibiotic prophylaxis (AP) to avoid the spread of multi-drug resistant (MDR) bacteria. An antimicrobial stewardship program and a patient-tailored antibiotic prophylaxis could be an optimal strategy to reduce the impact of infectious complications after pancreatic surgery. However, few data are available regarding this topic. Objective: To evaluate the useful of an antimicrobial stewardship program and a patient-tailored antibiotic prophylaxis in the reduction of the occurrence of SSI and the inappropriate use of key antibiotics in patients undergoing pancreatic surgery. Study design: A time series study will be conducted. The antimicrobial stewardship program is shared between three national high-volume centers of pancreatic surgery. Statistical significance and effect size were calculated by segmented regression analysis of interrupted time series of drug use, SSI rate, and costs for 3 years before and after the introduction of the program. Study population: Patients with an indication for elective pancreatic surgery. Main study parameters/endpoints: Primary outcome is the reduction of SSI rate. Secondary outcomes are the reduction of the use of the key antibiotics (such as piperacillin/tazobactam and carbapenems), the microbial whole-genome sequencing (WGS) of the carbapenemase-producing Enterobacteriaceae, and the reduction of the treatment costs

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. An Antimicrobial Stewardship Program in Pancreatic Surgery Reduces the Infectious Risk of Colonized Bile, Reducing the Predictive Value of the Intraoperative Bile Culture: A Before-after Study on 1638 Pancreatoduodenectomies.
    De Pastena M, Paiella S, Lionetto G, Casciani F, et al · · 2025 · cited 1× · PMID 40747933 · DOI 10.1097/sla.0000000000006870

Verify or expand the search:

Other recruiting trials for Surgical Site Infection

Currently open trials in the same condition.

Other Azienda Ospedaliera Universitaria Integrata Verona trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04199494.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing